Children’s Hospital Colorado pioneered prenatal therapy for cystic fibrosis, moving intervention earlier in life to target CF before birth. The approach was reported during Cystic Fibrosis Awareness Month coverage, emphasizing that prenatal treatment could represent a new shift from postnatal diagnosis toward earlier disease modification. While the article did not provide trial endpoints in the prompt text, the positioning is clinically significant because CF prevention and early intervention strategies are emerging alongside newborn screening expansions and mutation-tailored therapeutics. For the biotech audience, prenatal CF work adds pressure to validate safety, adherence, and developmental outcomes in addition to disease-control endpoints, which can differ materially from standard pediatric initiation windows.